JAMA ONCOL:美国成人胶质瘤发病率以及不同种族之间的预后差别

2018-07-04 MedSci MedSci原创

胶质瘤是美国最常见的恶性脑肿瘤,其发病率在不同年龄,性别和种族之间并不相同,脑肿瘤确诊后的生存情况也存在差异。JAMA ONCOL近期发表了一篇文章,研究不同种族胶质瘤发病率和生存情况。

胶质瘤是美国最常见的恶性脑肿瘤,其发病率在不同年龄,性别和种族之间并不相同,脑肿瘤确诊后的生存情况也存在差异。JAMA ONCOL近期发表了一篇文章,研究不同种族胶质瘤发病率和生存情况。

作者通过SEER数据库检索2000年1月1日至2014年12月31日之间的数据。根据胶质瘤病理类型,种族,西班牙裔,性别和年龄分组分别计算发病率。根据胶质瘤病理类型,种族,西班牙裔和保险情况计算1年和5年相关生存率。最终共纳入18岁以上的胶质瘤患者244808例。这些患者中,150631例为胶质母细胞瘤,46002例为星形细胞瘤,26068例少突胶质细胞瘤,8816例为室管膜瘤,13291例为其他类型胶质瘤。男性137733例,女性107075例。有204580例非西班牙裔白人,17321例西班牙裔白人,14566例黑人,1070例印第安人或阿拉斯加原住民,5947例亚洲人。非西班牙裔白人的胶质母细胞瘤,星形细胞瘤和少突胶质细胞瘤发病率高于西班牙裔白人,黑人,印第安人或阿拉斯加原住民和亚洲人。各个种族人群中,男性发病率均高于女性。大部分肿瘤在45岁以上时发生,各个年龄组中不同种群的发病率距有差别。西班牙裔白人,黑人和亚洲人胶质瘤诊断后生存情况相似,但是非西班牙裔白人的生存情况较差,且与治疗类型无关。

文章最后认为,不同种族胶质瘤发病率和1年,5年生存率差异显着,非西班牙裔白人发病率更高且生存率更低。这一研究结果有助于未来进一步寻找胶质瘤危险因素。

原始出处:
Quinn T.Ostrom,David J.Cote,et al.Adult Glimo Incidence and Survival by Race or Ethnity in the United States From 2000 to 2014.JAMA ONCOL.June 21 2018 doi:10.1001/jamaoncol.2018.1789

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1823474, encodeId=eb4918234e41e, content=<a href='/topic/show?id=b2873e9220e' target=_blank style='color:#2F92EE;'>#发病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37922, encryptionId=b2873e9220e, topicName=发病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Sat Oct 27 00:50:00 CST 2018, time=2018-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1865478, encodeId=f1f618654e815, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Mon Oct 15 04:50:00 CST 2018, time=2018-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=329377, encodeId=458f3293e7fe, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Thu Jul 05 01:20:15 CST 2018, time=2018-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=329339, encodeId=07d632933900, content=谢谢分享学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM7GibvIBibibnnnvpajk2stlDF5oichYahI6Bia8uxeTBFoPbdoHWebyXf9eal9FNgUF2lNcrwoZicM3BvQ/0, createdBy=a3742066385, createdName=戒馋,懒,贪, createdTime=Wed Jul 04 22:56:04 CST 2018, time=2018-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=329332, encodeId=48cf329332d1, content=学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Wed Jul 04 22:27:31 CST 2018, time=2018-07-04, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1823474, encodeId=eb4918234e41e, content=<a href='/topic/show?id=b2873e9220e' target=_blank style='color:#2F92EE;'>#发病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37922, encryptionId=b2873e9220e, topicName=发病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Sat Oct 27 00:50:00 CST 2018, time=2018-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1865478, encodeId=f1f618654e815, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Mon Oct 15 04:50:00 CST 2018, time=2018-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=329377, encodeId=458f3293e7fe, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Thu Jul 05 01:20:15 CST 2018, time=2018-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=329339, encodeId=07d632933900, content=谢谢分享学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM7GibvIBibibnnnvpajk2stlDF5oichYahI6Bia8uxeTBFoPbdoHWebyXf9eal9FNgUF2lNcrwoZicM3BvQ/0, createdBy=a3742066385, createdName=戒馋,懒,贪, createdTime=Wed Jul 04 22:56:04 CST 2018, time=2018-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=329332, encodeId=48cf329332d1, content=学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Wed Jul 04 22:27:31 CST 2018, time=2018-07-04, status=1, ipAttribution=)]
    2018-10-15 minlingfeng
  3. [GetPortalCommentsPageByObjectIdResponse(id=1823474, encodeId=eb4918234e41e, content=<a href='/topic/show?id=b2873e9220e' target=_blank style='color:#2F92EE;'>#发病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37922, encryptionId=b2873e9220e, topicName=发病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Sat Oct 27 00:50:00 CST 2018, time=2018-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1865478, encodeId=f1f618654e815, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Mon Oct 15 04:50:00 CST 2018, time=2018-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=329377, encodeId=458f3293e7fe, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Thu Jul 05 01:20:15 CST 2018, time=2018-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=329339, encodeId=07d632933900, content=谢谢分享学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM7GibvIBibibnnnvpajk2stlDF5oichYahI6Bia8uxeTBFoPbdoHWebyXf9eal9FNgUF2lNcrwoZicM3BvQ/0, createdBy=a3742066385, createdName=戒馋,懒,贪, createdTime=Wed Jul 04 22:56:04 CST 2018, time=2018-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=329332, encodeId=48cf329332d1, content=学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Wed Jul 04 22:27:31 CST 2018, time=2018-07-04, status=1, ipAttribution=)]
    2018-07-05 1209e435m98(暂无昵称)

    学习了.谢谢分享

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1823474, encodeId=eb4918234e41e, content=<a href='/topic/show?id=b2873e9220e' target=_blank style='color:#2F92EE;'>#发病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37922, encryptionId=b2873e9220e, topicName=发病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Sat Oct 27 00:50:00 CST 2018, time=2018-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1865478, encodeId=f1f618654e815, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Mon Oct 15 04:50:00 CST 2018, time=2018-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=329377, encodeId=458f3293e7fe, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Thu Jul 05 01:20:15 CST 2018, time=2018-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=329339, encodeId=07d632933900, content=谢谢分享学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM7GibvIBibibnnnvpajk2stlDF5oichYahI6Bia8uxeTBFoPbdoHWebyXf9eal9FNgUF2lNcrwoZicM3BvQ/0, createdBy=a3742066385, createdName=戒馋,懒,贪, createdTime=Wed Jul 04 22:56:04 CST 2018, time=2018-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=329332, encodeId=48cf329332d1, content=学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Wed Jul 04 22:27:31 CST 2018, time=2018-07-04, status=1, ipAttribution=)]
    2018-07-04 戒馋,懒,贪

    谢谢分享学习了

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1823474, encodeId=eb4918234e41e, content=<a href='/topic/show?id=b2873e9220e' target=_blank style='color:#2F92EE;'>#发病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37922, encryptionId=b2873e9220e, topicName=发病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Sat Oct 27 00:50:00 CST 2018, time=2018-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1865478, encodeId=f1f618654e815, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Mon Oct 15 04:50:00 CST 2018, time=2018-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=329377, encodeId=458f3293e7fe, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Thu Jul 05 01:20:15 CST 2018, time=2018-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=329339, encodeId=07d632933900, content=谢谢分享学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM7GibvIBibibnnnvpajk2stlDF5oichYahI6Bia8uxeTBFoPbdoHWebyXf9eal9FNgUF2lNcrwoZicM3BvQ/0, createdBy=a3742066385, createdName=戒馋,懒,贪, createdTime=Wed Jul 04 22:56:04 CST 2018, time=2018-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=329332, encodeId=48cf329332d1, content=学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Wed Jul 04 22:27:31 CST 2018, time=2018-07-04, status=1, ipAttribution=)]
    2018-07-04 医者仁心5538

    学习一下

    0

相关资讯

胶质瘤多学科诊治(MDT)中国专家共识

在国外,多学科综合治疗协作组(MDT)已成为肿瘤治疗的标准。 2008年在中华医学会神经外科学分会的领导下,发表了多学科专家编写的《中国中枢神经系统恶性胶质瘤诊断和治疗共识》,随在2011年进行了更新和扩容编写成指南,并于2015年再次更新,新指南推荐MDT模式治疗脑胶质瘤。

CLIN CANCER RES:Fibulin-3抗体靶向治疗胶质瘤

胶质瘤分子异质性和侵袭能力是成功治疗这种恶性肿瘤的两大主要障碍。靶向肿瘤细胞外基质(ECM)可能有助于克服这两大障碍,因为肿瘤细胞分泌的ECM分子是肿瘤侵袭的关键。Fibulin-3是构成胶质瘤ECM骨架的糖蛋白,通过启动Notch和NFκB信号促进肿瘤进展。CLIN CANCER RES近期发表了一篇文章,研究靶向ECM中的信号分子治疗胶质瘤。

Radiology: DCE和DSE MR成像在大脑胶质瘤的多种中心标准化评估

目的:通过多中心获取并分析动态增强(DCE)及动态磁敏感增强(DSE)标准MR成像序列的可行性,以2016年世界卫生组织肿瘤新的分类为依据,预测并验证肿瘤级别的准确性,并将结果发表在Radiology上。

CLIN CANCER RES:IDO1抑制剂增强放疗联合PD-1阻断对晚期胶质瘤的疗效

胶质瘤是成人恶性程度最高的原发脑肿瘤,中位生存期为15到20个月。各种治疗方案的临床Ⅲ期试验均对如何治疗胶质瘤进行了研究,包括近期的免疫检查点抑制剂,纳武单抗(抗PD-1)。该疗法并未改善胶质瘤复发患者的预后。免疫检查点抑制治疗在其他肿瘤中有良好的前景,因此胶质瘤的治疗不能放弃这一方案,目前的研究正在评估这一疗法联合其他药物的治疗效果。CLIN CANCER RES近期发表了一篇文章,研究这一问题

Radiology:动态对比增强和动态敏感对比磁共振在脑胶质瘤的多中心标准化评估。

评估在多中心临床环境下动态对比增强(DCE)和动态磁敏感对比(DSC)磁共振(MR)成像采集和分析的标准化方案的可行性,并根据新的世界卫生组织2016年分类验证其对于胶质瘤级别预测的准确性。

胶质瘤放疗中国专家共识(2017)

胶质瘤是指起源于神经胶质细胞的肿瘤,是最常见的原发性颅内肿瘤,WHO中枢神经系统肿瘤分类将胶质瘤分为WHO Ⅰ—Ⅳ级,WHOⅠ、Ⅱ级为低级别胶质瘤,Ⅲ、Ⅳ级为高级别胶质瘤。随着现代放疗技术的发展和放射生物学的深入研究,放射治疗已成为胶质瘤的重要治疗手段之一,不同级别胶质瘤的特点不同,放射治疗原则也不尽相同。2016年,我国发布了《中国中枢神经系统胶质瘤诊断与治疗指南》,阐述了胶质瘤的诊断和综合治疗